FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

OMB APPROVAL

hours per response:

| OMB Number:           | 3235-0287 |
|-----------------------|-----------|
| Estimated average bur | den       |

0.5

#### Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| 10b5-1(c). See In | struction 10.             |          |  |  |
|-------------------|---------------------------|----------|--|--|
| 1. Name and Addre | ss of Reporting Pers      | son*     | 2. Issuer Name and Ticker or Trading Symbol BioSig Technologies, Inc. [ BSGM ] | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  X Director 10% Owner  |
| (Last)            | (First)                   | (Middle) | 3. Date of Earliest Transaction (Month/Day/Year) 06/07/2024                    | Officer (give title Other (specify below) below)   |
| 55 GREENS FA      | ECHNOLOGIES,<br>ARMS ROAD | , INC.   | If Amendment, Date of Original Filed (Month/Day/Year)                          | Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person     Form filed by More than One Reporting Person |
| WESTPORT          | CT                        | 06880    |  |  |
| (City)            | (State)                   | (Zip)    |  |  |

## Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction<br>Date<br>(Month/Day/Year) | <br>Transaction Code (Instr. |   | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) |               |                           | 5. Amount of<br>Securities<br>Beneficially Owned<br>Following Reported | Form: Direct (D) | Beneficial<br>Ownership |
|---------------------------------|--|------------------------------|---|---|---------------|---------------------------|--|------------------|-------------------------|
|                                 |  | Code                         | v | Amount  | (A) or<br>(D) | Price                     | Transaction(s)<br>(Instr. 3 and 4)                                     |                  | (Instr. 4)              |
| Common Stock                    | 06/07/2024                                 | A                            |   | 50,000  | A             | <b>\$0</b> <sup>(1)</sup> | 559,501  | D                |                         |

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of<br>Derivative<br>Security (Instr. 3) | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) | '    |   | 5. Number of<br>Derivative<br>Securities<br>Acquired (A)<br>or Disposed of<br>(D) (Instr. 3, 4<br>and 5) |     | 6. Date Exercisable and<br>Expiration Date<br>(Month/Day/Year) |                    | 7. Title and Amount of<br>Securities Underlying<br>Derivative Security<br>(Instr. 3 and 4) |                                     | Derivative<br>Security<br>(Instr. 5) | 9. Number of<br>derivative<br>Securities<br>Beneficially<br>Owned<br>Following<br>Reported | Form:<br>Direct (D) | 11. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |
|--|---|---|------|---|--|-----|--|--------------------|--|-------------------------------------|--------------------------------------|--|---------------------|--|
|  |   |   | Code | v | (A)  | (D) | Date<br>Exercisable  | Expiration<br>Date | Title  | Amount<br>or<br>Number<br>of Shares |                                      | Transaction(s)<br>(Instr. 4)   |                     |  |

## Explanation of Responses:

1. The shares of restricted stock were granted for services and were fully vested as of June 7, 2024, the date of the grant, based on a closing price of \$1.865 per share.

### Remarks:

Exhibit 24.1 Power of Attorney (furnished herewith)

/s/ Anthony Amato attorney-in-

**fact** 

\*\* Signature of Reporting Person

07/05/2024

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

### POWER OF ATTORNEY

June 21, 2024

KNOW ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Anthony Amato as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for, in the name of, and on behalf of the undersigned, place and stead, in any and all capacities, (i) to execute any and all filings required to be made by the undersigned in the undersigned's capacity as an officer or director or both of BioSig Technologies, Inc. pursuant to Section 13 or Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") (or any similar rule with respect to foreign exchanges) or any rule or regulation thereunder (including any amendment, supplement, and/or exhibit thereto), for, in the name of, and on behalf of the undersigned (ii) to do and perform any and all acts for, in the name of, and on behalf of the undersigned which said attorney-in-fact determines may be necessary or appropriate to complete and execute any and all such filings, amendments, supplements, and/or exhibits, and any and all other document(s) in connection therewith, (iii) to file such filings, amendments, supplements, exhibits, and/or documents with any governmental office or agency, whether U.S., foreign, state or local government (including, without limitation, the U.S. Securities and Exchange Commission and state securities administrators or commissions), or any stock exchange or stock quotation system (including, without limitation, The NASDAQ Capital Market), as may be required under applicable laws or rules and regulations of any stock exchange or stock quotation system, and (iv) to perform any and all other acts that, in the opinion of said attorney-in-fact and agent, may be of benefit to, in the best interest of, or legally required by or for the undersigned, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises, as fully to all intents and purposes as th

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file reports under Section 13 or Section 16 of the Exchange Act (or any similar rule with respect to foreign exchanges) or any rule or regulation thereunder (including any amendment, supplement, and/or exhibit thereto), unless earlier revoked by the undersigned in a signed writing delivered to Anthony Amato.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed and effective as of the date first written above.

/s/ Frederick D. Hrkac

Frederick D. Hrkac